期刊
AMERICAN JOURNAL OF HEMATOLOGY
卷 84, 期 2, 页码 71-73出版社
WILEY-LISS
DOI: 10.1002/ajh.21328
关键词
-
类别
资金
- NCI NIH HHS [U10 CA025224, R21 CA121569-02, CA25224, R21 CA121569, CA121569, R01 CA092104] Funding Source: Medline
Serum B-lymphocyte stimulator (BLyS) levels are elevated in a subset of non-Hodgkin lymphoma (NHL) patients, particularly those with a family history of B-cell malignancies or a polymorphism in the BLyS gene. BLyS promotes growth of malignant B-cells and increased serum BLyS levels are associated with a poor clinical outcome. In this study, BLyS levels were measured before and after 4 weekly doses of rituximab in 30 patients with previously untreated follicular Grade 1 NHL. A significant increase was seen in the serum levels of BLyS (P = 0.0001) after rituximab therapy. The increase was independent of genetic variability in the BLyS gene. Am. J. Hematol. 84:71-73, 2009. (C) 2008 Wiley-Liss, Inc.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据